Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs iShares MSCI Malaysia ETF (EWM) Price & Performance

Citius Pharmaceuticals IncTrade
iShares MSCI Malaysia ETFTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs iShares MSCI Malaysia ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while iShares MSCI Malaysia ETF trades at $28.07. The key difference: iShares MSCI Malaysia ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CTXREWM
Market Cap
$20.01M
Sector
HealthBroad Market / Factor
52-Week High
$1.82$30.42
52-Week Low
$0.48$24.73
Enterprise Value
$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.

The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.

iShares MSCI Malaysia ETF

EWM (iShares MSCI Malaysia ETF) trades at $28.18, up 0.28% with a bullish technical signal from moving averages. The ETF offers concentrated exposure to Malaysia's financial (54%) and industrial (21%) sectors, benefiting from data center expansion and tourism initiatives. Key support and resistance cluster around $28, with neutral oscillators suggesting balanced momentum.

Outlook remains positive due to Malaysia's structural growth drivers, though financial ratios are unavailable. Risks include energy supply constraints and regional currency volatility. Institutional sentiment leans bullish with 11 buy signals, but investors should monitor Malaysia's economic policies and global macro conditions.

Returns comparison

Trailing returns across standard periods

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About iShares MSCI Malaysia ETF

EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.

Read more on EWM